Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1989-3-22
|
pubmed:abstractText |
A randomized, placebo-controlled, double-blind clinical trial was performed to test the hypothesis that a 2-g single dose of metronidazole for male partners of women with bacterial vaginosis was more effective than placebo in improving cure rate and decreasing recurrence rate. In addition, the effectiveness of a 2-g single dose of metronidazole was compared with a seven-day course of 500 mg of metronidazole twice a day in patients with bacterial vaginosis. Statistically significant benefits of partner treatment were noted in the initial cure rate by Gram-stained smear criteria (P less than .01) and in percentage of women with symptoms eight weeks after initiating therapy (P less than .05). The seven-day course of metronidazole was superior to the single-dose regimen in the percentage of patients with clue cells and the percentage of patients with a positive "sniff" test at the first follow-up visit; however, differences in the initial cure rate assessed by clinical criteria and Gram-stained smear criteria were not statistically significant between the two patient treatment regimens. Recurrence rates by Gram-stained smear criteria between patient and partner treatment groups at five and eight weeks after initiation of treatment were also not significantly different between the two patient regimens. Single-dose metronidazole treatment of the sexual partner of women with bacterial vaginosis improves initial bacterial vaginosis cure rates. The seven-day course of metronidazole was not found by statistical analysis to be significantly superior to single-dose therapy when considering initial cure rates by clinical or Gram-stained smear criteria or recurrence rates.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0094-3509
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
163-71
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2644391-Adult,
pubmed-meshheading:2644391-Bacterial Infections,
pubmed-meshheading:2644391-Clinical Trials as Topic,
pubmed-meshheading:2644391-Double-Blind Method,
pubmed-meshheading:2644391-Drug Administration Schedule,
pubmed-meshheading:2644391-Female,
pubmed-meshheading:2644391-Humans,
pubmed-meshheading:2644391-Male,
pubmed-meshheading:2644391-Metronidazole,
pubmed-meshheading:2644391-Random Allocation,
pubmed-meshheading:2644391-Recurrence,
pubmed-meshheading:2644391-Sexual Partners,
pubmed-meshheading:2644391-Vaginal Diseases
|
pubmed:year |
1989
|
pubmed:articleTitle |
The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis.
|
pubmed:affiliation |
Department of Family Medicine, School of Medicine, University of Washington, Seattle.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|